SE9603480D0 - Dosage form for hard soluble drugs - Google Patents

Dosage form for hard soluble drugs

Info

Publication number
SE9603480D0
SE9603480D0 SE9603480A SE9603480A SE9603480D0 SE 9603480 D0 SE9603480 D0 SE 9603480D0 SE 9603480 A SE9603480 A SE 9603480A SE 9603480 A SE9603480 A SE 9603480A SE 9603480 D0 SE9603480 D0 SE 9603480D0
Authority
SE
Sweden
Prior art keywords
forming
dosage form
gel
soluble drugs
drug
Prior art date
Application number
SE9603480A
Other languages
Swedish (sv)
Other versions
SE9603480L (en
Inventor
Johan Carlfors
Katarina Lindell
Original Assignee
Johan Carlfors
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johan Carlfors filed Critical Johan Carlfors
Priority to SE9603480A priority Critical patent/SE9603480L/en
Publication of SE9603480D0 publication Critical patent/SE9603480D0/en
Priority to PCT/SE1997/001592 priority patent/WO1998011874A1/en
Priority to JP10514594A priority patent/JP2001501194A/en
Priority to AU44077/97A priority patent/AU4407797A/en
Publication of SE9603480L publication Critical patent/SE9603480L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Abstract

An in situ gel forming pharmaceutical composition for local administration to a target organ in the body, said composition essentially consisting of a water solution containing one or more aggregate forming surfactants, one or more gel forming water soluble polymers, a drug and optionally excipients, said drug having lipophilic properties, as it binds stronger to the aggregates of surfactants than to water, whereby its release from the in situ forming gel to the target organ occurs slowly.
SE9603480A 1996-09-23 1996-09-23 Dosage form for hard soluble drugs SE9603480L (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE9603480A SE9603480L (en) 1996-09-23 1996-09-23 Dosage form for hard soluble drugs
PCT/SE1997/001592 WO1998011874A1 (en) 1996-09-23 1997-09-22 Pharmaceutical composition forming a gel
JP10514594A JP2001501194A (en) 1996-09-23 1997-09-22 Gel-forming pharmaceutical composition
AU44077/97A AU4407797A (en) 1996-09-23 1997-09-22 Pharmaceutical composition forming a gel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603480A SE9603480L (en) 1996-09-23 1996-09-23 Dosage form for hard soluble drugs

Publications (2)

Publication Number Publication Date
SE9603480D0 true SE9603480D0 (en) 1996-09-23
SE9603480L SE9603480L (en) 1998-03-24

Family

ID=20404002

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9603480A SE9603480L (en) 1996-09-23 1996-09-23 Dosage form for hard soluble drugs

Country Status (4)

Country Link
JP (1) JP2001501194A (en)
AU (1) AU4407797A (en)
SE (1) SE9603480L (en)
WO (1) WO1998011874A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
FR2777189B1 (en) * 1998-04-09 2001-04-06 Chauvin Lab Sa OPHTHALMIC COMPOSITION COMPRISING A BETA-BLOCKER
ATE243038T1 (en) 1999-11-01 2003-07-15 Alcon Inc PHARMACEUTICAL COMPOSITIONS CONTAINING A FLUOROCHINOLONE ANTIBIOTIC AND XANTHANG GUM
ES2225573T3 (en) 2000-07-28 2005-03-16 Alcon, Inc PHARMACEUTICAL COMPOSITIONS CONTAINING TOBRAMYCIN AND XANTANA GUM.
SE0103369D0 (en) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
FR2840614B1 (en) 2002-06-07 2004-08-27 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2855521B1 (en) 2003-05-28 2005-08-05 Flamel Tech Sa POLYAMINOACIDES FUNCTIONALIZED BY AT LEAST ONE YDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS.
KR20120005052A (en) * 2003-08-21 2012-01-13 수캄포 아게 Ophthalmic composition
ITPD20040245A1 (en) * 2004-10-08 2005-01-08 Fidia Advanced Biopolymers Srl BIOMATERIALS MADE UP OF HYALURONIC ACID, SULFATE AND GELL, USABLE IN THE PREVENTION OF SPINAL ADHESIONS
FR2876581B1 (en) 2004-10-20 2007-05-18 Interpharm Dev BIOADHESIVE COMPOSITION WITH PROGRAMMED RELEASE
US20090036404A1 (en) * 2007-08-02 2009-02-05 Macleod Steven K Ophthalmic compositions comprising a carboxyl-modified fructan or a salt thereof
US20150099751A1 (en) * 2013-10-07 2015-04-09 King Abdulaziz University In situ gel loaded with phosphodiesterase type v inhibitors nanoemulsion
CN106727276A (en) * 2015-11-22 2017-05-31 中国人民解放军第三军医大学 In-situ gel preparation and application thereof
CA3042729C (en) * 2017-09-02 2021-12-07 Iview Therapeutics, Inc. In situ gel-forming pharmaceutical compositions and uses thereof for sinus diseases

Also Published As

Publication number Publication date
AU4407797A (en) 1998-04-14
JP2001501194A (en) 2001-01-30
WO1998011874A1 (en) 1998-03-26
SE9603480L (en) 1998-03-24

Similar Documents

Publication Publication Date Title
SE9603480D0 (en) Dosage form for hard soluble drugs
ATE235895T1 (en) DRUG DELIVERY SYSTEM CONTAINING A HARD-PACKED, SOLID DRUG BASE
ATE264114T1 (en) CYCLODEXRINE POLYMERS FOR USE AS DRUG CARRIERS
BR9808888A (en) Dosage forms and method of improving male erectile dysfunction
MXPA05003591A (en) Cyclodextrin-based materials, compositions and uses related thereto.
DE60023520D1 (en) LIQUID HIGH VISIBLE SYSTEM WITH CONTROLLED RELEASE AND MEDICAL OR SURGICAL DEVICE
BR9405798A (en) Methods for in vivo release of biological material and useful compositions thereof
EA200501810A1 (en) COMPOSITION OF CONJUGATED MEDICINE
FR2808685B1 (en) PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ANTI-INFLAMMATORY AGENTS
ATE417604T1 (en) SUSTAINED RELEASE MATRIX FOR HIGH DOSE INSOLUBLE DRUGS
BRPI0015567B8 (en) compound, pharmaceutical composition, dosage unit form, use of the pharmaceutical composition and method for preparing a pharmaceutical composition
CY1109861T1 (en) INTERDERATIVE THERAPEUTIC SYSTEM FOR PARKINI DISEASE Causing High Plasma Rotigotine Level
BR9713237A (en) Alfuzosin hydrochloride controlled-release tablet
CY1105849T1 (en) USE OF ANTIseptics IN THE COMMERCIAL MANUFACTURE OF A PHARMACEUTICAL PREPARATION FOR THE PREVENTION OR TREATMENT OF INFLAMMATION WITHIN THE HUMAN BODY
BR0115965A (en) Pharmaceutical compositions for oral release of pharmacologically active agents
BR9914360A (en) N-aralkylaminotetralins as ligands for neuropeptide receptor yy5
BR9607234A (en) Mucoadhesive granules use the same process for their preparation, pharmaceutical composition and use
CY1108863T1 (en) PHARMACEUTICAL PREPARATION OF EXTREMELY INDEPENDENT RELEASE FROM RI
ATE292453T1 (en) ANTIVIRAL DRUG
TR200102107T2 (en) Tumor necrosis factor antagonists and their use in endometriosis.
TR200101719T2 (en) The use of apomorphine in drug manufacture for the treatment of organic erectile dysfunction in men
EA200600817A1 (en) ANTAGONISTS B1 BRADIKININ RECEPTOR (OPTIONS), PHARMACEUTICAL COMPOSITION, MEDICINAL MEDICINE, METHOD OF TREATMENT OF DISEASES (OPTIONS)
BR0009472A (en) Lhrh antagonists with improved solubility properties
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
DE50115451D1 (en) PHARMACEUTICAL COMPOSITION FOR THE NASAL APPLICATION OF FENTANYL

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 9603480-6